Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Ten deals. Twenty-five billion dollars. Five months. Lilly is not just the most acquisitive pharma company of 2026. It is executing the most concentrated M&A campaign in the history of the industry. The three vaccine acquisitions announced Tuesday mark a new strategic front: infectious disease prevention. Curevo's shingles vaccine challenges GSK's Shingrix, a $5.6B franchise, with a next-generation synthetic adjuvant designed to reduce the side effects that keep vaccination rates low. LimmaTech targets the antimicrobial resistance crisis with vaccines against Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. Vaccine Company is developing an EBV nanoparticle vaccine, which is significant because Epstein-Barr virus is now established as the leading cause of multiple sclerosis and is linked to several cancers. Skovronsky's framing was deliberate: "Decades of evidence now link common infections to diseases that potentially emerge years later." Lilly is moving upstream from treating chronic disease to preventing it. The deal structure is consistent across all three: upfront payments plus clinical and regulatory milestones. No premiums were disclosed because all three targets are private. Fierce Biotech described the pace as "almost weekly" and noted it shows "no sign of letting up." Lilly shares rose 0.9% after the announcements. 👉 Read Full Analysis

🔮 What To Watch

🚀 Top Story

Lilly Acquires Three Vaccine Developers for $3.83B Combined LLY

What Happened: Eli Lilly announced on May 26 agreements to acquire three privately held vaccine companies in simultaneous transactions totaling up to $3.83B.

Curevo (up to $1.5B): Developing amezosvatein, a shingles vaccine using a next-generation synthetic adjuvant. In Phase 2 testing, amezosvatein matched the immunogenicity of the standard shingles shot (GSK's Shingrix) while reducing activity-limiting side effects. Phase 2 extension enrolled 640 additional participants in 2025. Curevo raised $110M last year to fund the extension. Challenges GSK's Shingrix directly.

LimmaTech Biologics (up to $780M): Developing vaccines against bacterial pathogens where rising antimicrobial resistance is closing therapeutic options. Lead program LTB-SA7 is in Phase 1 for Staphylococcus aureus (leading cause of surgical infections). Pipeline also includes vaccines for Neisseria gonorrhoeae and Chlamydia trachomatis. Platform targets bacterial toxins and superantigens to generate broad, durable immune responses.

Vaccine Company (up to $1.55B): Developing a five-antigen Epstein-Barr virus (EBV) vaccine using proprietary Vivo Nanoparticle technology. Currently preclinical (Phase 1 ready). EBV is now established as the leading cause of multiple sclerosis and is linked to several cancers including nasopharyngeal carcinoma and Hodgkin lymphoma. Received an ARPA-H grant in 2024.

Executive Impact: CSO Skovronsky said: "Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention." The three acquisitions give Lilly a diversified infectious disease portfolio spanning viral prevention (shingles, EBV) and bacterial prevention (staph, STIs), with technology platforms ranging from synthetic adjuvants to nanoparticles to toxin-targeting immunology.

Lilly's 2026 M&A Running Total:

Total announced value: approximately $25.9B across 10 deals in under five months.

🔬 Clinical & Research Updates

Lilly's Verve Base Editor Shows Early Promise in Cholesterol LLY

BioSpace reported that Lilly's investment in Verve Therapeutics is producing returns: a base editing approach to permanently lower cholesterol showed positive results in an early clinical study. Base editing makes precise single-letter changes to DNA without cutting both strands (unlike CRISPR), potentially reducing the risk of unintended genetic changes. If the approach works at scale, a single treatment could permanently lower LDL cholesterol, eliminating the need for daily statins or periodic PCSK9 injections. This complements the new AHA/ACC LDL guidelines we covered two weeks ago and Lilly's broader cardiovascular ambitions.

📅 The Week Ahead

👉 Read Full Analysis

Lilly has not been in the vaccine business for decades. The decision to enter now, with three acquisitions simultaneously, reflects a strategic thesis that is emerging across the industry: prevention is more valuable than treatment.

The logic: if EBV causes multiple sclerosis (and the evidence is now strong), preventing EBV infection could prevent MS. That could reduce the need for MS drugs, a multi-billion dollar global market. If S. aureus surgical infections can be prevented by vaccination, that reduces hospital costs, antibiotic use, and the AMR crisis. If shingles vaccination rates increase because of a better-tolerated vaccine, that reduces the burden of post-herpetic neuralgia and its associated healthcare costs.

Lilly is essentially betting that the most valuable medicines of the next decade will be the ones that prevent diseases before they start, not the ones that treat them after they develop. The GLP-1 franchise (treating obesity) funds the vaccine franchise (preventing infection-driven disease). The obesity business generates the cash. The vaccine business invests it in prevention.

This is a long-term thesis. None of these vaccine candidates will generate revenue before 2028 at the earliest (Curevo is closest, in Phase 2 extension). But the strategic positioning is clear: Lilly wants to be in the business of keeping people healthy, not just treating them when they are sick.

💊 Curevo vs. Shingrix

GSK's Shingrix is a multi-billion dollar franchise but has a well-documented tolerability problem. A significant majority of patients report injection-site reactions, and many report systemic reactions (fever, fatigue, headache) that limit activity for 1 to 2 days. These side effects are driven by the AS01B adjuvant system.

Curevo's amezosvatein uses a synthetic adjuvant designed to maintain the immune response while reducing the reactogenicity. Phase 2 data showed matched immunogenicity versus Shingrix with "reduced activity-limiting reactogenicity." If Phase 3 confirms this profile, Curevo would offer the same protection with fewer side effects, a clear value proposition for patients, physicians, and payers.

The shingles market is large (approximately 1 million U.S. cases per year) and underpenetrated, partly because of tolerability concerns with existing vaccines. A better-tolerated vaccine could significantly expand the vaccinated population.

📊 Lilly by the Numbers: 2026

🎯 Catalyst Calendar: ASCO Week and Beyond

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →